Cite
HARVARD Citation
Porter, C. et al. (2016). Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. Journal of reproductive immunology. pp. 7-12. [Online].